RxDoctor Payments Data

Prakash Acharya, MD

Interventional Cardiology · Columbia, MONPI 1912306895

Payments from drug & device makers

$6,531in general payments, 2019–2025

Across 77 payments — averaging $84.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Medtronic$831
  • Teleflex LLC$489
  • Biotronik Inc.$417
  • Boston Scientific$346
  • Abiomed$196
  • plus $692 from 12 others

What the payments were for

  • Travel & lodging$1,96530%
  • Food & beverage$4,50469%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,531 in reported general payments places this provider in the 30th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$236,061
Medicare patients
828
Services billed
2,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$169,629
JardianceEmpagliflozin104$111,109
EntrestoSacubitril/Valsartan35$34,526
Repatha SureclickEvolocumab19$31,135
BrilintaTicagrelor39$20,730
MultaqDronedarone Hcl16$20,677
Praluent PenAlirocumab22$20,064
Metoprolol Succinate345$3,889
Atorvastatin Calcium238$2,061
ClopidogrelClopidogrel Bisulfate133$1,650
Rosuvastatin Calcium58$1,636
Nitroglycerin26$1,614
Losartan Potassium205$1,448
Amlodipine Besylate288$1,380
Carvedilol181$1,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$22$111,109104 claims
AstraZenecaBrilinta$58$20,73039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →